证券代码：688062 证券简称：迈威生物 公告编号：2025-035 迈威（上海）生物科技股份有限公司 关于回购股份事项前十大股东和前十大无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈威（上海）生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第二届董事会第十九次会议，审议通过了《关于以集中竞价交易方式 回购股份方案的议案》，同意公司通过上海证券交易所交易系统以集中竞价交易 方式回购公司已发行的部分人民币普通股（A 股）股份。具体内容请详见公司于 2025 年 6 月 27 日在上海证券交易所网站（www.sse.com.cn）披露的《迈威（上 海）生物科技股份有限公司关于以集中竞价交易方式回购股份方案的公告》（公 告编号：2025-029）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司董事会公告股份回购方案决议前一个 交易日（2025 年 6 月 26 日）登记在册的前十大股东和前十大无限售 ...

Core Viewpoint - Gastrointestinal (GI) cancers, including liver, stomach, pancreatic, neuroendocrine tumors, and colorectal cancer, are major causes of cancer-related deaths globally, accounting for approximately 24.6% of all cancer diagnoses and 34.2% of cancer deaths [2] Group 1: Cancer Statistics and Challenges - Colorectal cancer (CRC) ranks third in incidence and second in mortality among all cancers globally, while pancreatic cancer, despite its lower incidence, has the highest mortality rate [2] - Effective screening strategies are primarily limited to CRC, stomach, and esophageal cancers, leading to late-stage diagnoses in many cases, often with no possibility of cure [2] - Nearly 50% of patients diagnosed at an early stage may experience disease recurrence, resulting in poor overall prognosis [2] Group 2: Treatment Challenges and Innovations - Surgical interventions and postoperative chemotherapy have reduced mortality rates, but adverse reactions and drug resistance remain significant challenges [2] - Immunotherapy has emerged as a promising treatment method, yet its efficacy is currently limited to a small subset of patients, highlighting the urgent need for better therapeutic targets and new treatments in GI cancers [2] Group 3: Research on 7MW4911 - A recent study published in Cell Reports Medicine demonstrated that the CDH17-targeted antibody-drug conjugate (ADC) 7MW4911, conjugated with the DNA topoisomerase inhibitor MF-6, showed promising therapeutic effects against multidrug-resistant GI tumors in mouse models [3][6] - CDH17 is highly expressed in GI cancers, with nearly 100% expression in colorectal cancer clinical samples and 23%-88% in other GI cancers, correlating with tumor progression and poor clinical outcomes [5] - Preclinical evaluations indicated that 7MW4911 exhibited strong tumor-killing activity and significant tumor growth inhibition in various GI cancer models, along with favorable pharmacokinetics and safety profiles in non-human primate studies [7][8][10]

Group 1 - The core viewpoint of the news highlights the positive market sentiment in the biopharmaceutical sector driven by supportive government policies and significant milestones in innovative drug approvals [1][2] - The State Medical Insurance Administration and the National Health Commission issued 16 supportive policies for the high-quality development of innovative drugs, covering research, market access, hospital use, and payment [1] - The FDA's accelerated approval of DiZhe Pharmaceutical's EGFR Exon20ins targeted drug, Shuwozhe®, marks it as the first domestically developed innovative drug approved for this indication globally, further boosting market confidence [1] Group 2 - Guosheng Securities points out that the innovative drug sector within the biopharmaceutical industry is characterized by small and mid-cap pipeline blockbuster features, with a diversification trend in pain relief mechanisms [2] - Everbright Securities analyzes that the pharmaceutical industry's policies, driven by both medical insurance and commercial insurance, expand the market space for innovative drugs, with dynamic adjustments to the medical insurance catalog reducing the access cycle for innovative drugs [2] - Both institutions emphasize the policy dividends and clinical value realization in the innovative drug sector, aligning with the performance of innovative drug companies within the Sci-Tech Biopharmaceutical ETF [2]

Core Viewpoint - Google’s subsidiary Calico Life Sciences has entered into a nearly $600 million biopharmaceutical deal with Mabwell to acquire rights to a research therapy targeting Interleukin-11 (IL-11), including a clinical-stage monoclonal antibody 9MW3811 for age-related diseases [2][3]. Group 1: Deal Details - Mabwell has explored the therapeutic potential of 9MW3811 in age-related diseases during preclinical research, completing Phase 1 clinical studies in China and Australia, showing promise for treating idiopathic pulmonary fibrosis, and has received approval to conduct Phase 1 clinical studies in the United States [3]. - Under the licensing agreement, Mabwell grants Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 outside Greater China. Calico will pay an upfront non-refundable fee of $25 million, with potential additional payments of up to $571 million based on milestones, as well as tiered royalties based on net sales of the licensed product [3]. Group 2: Company Background - Calico was co-founded by Alphabet, Google's parent company, and industry leader Dr. Arthur Levinson, with the aim of understanding the biological principles of aging to help develop interventions that extend and improve lifespan. Calico has established partnerships with several organizations, including AbbVie and the Broad Institute of MIT and Harvard [3]. - Mabwell is an innovative biopharmaceutical company with a full industry chain layout, focusing on tumors and age-related diseases, covering treatment areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and infections [4].

Group 1 - In June, a total of 751 private equity managers participated in A-share listed company research, covering 387 stocks across 28 Shenwan primary industries, with a total of 1,769 research instances [1] - The most researched stock in June was Maiwei Biotechnology, which received 51 research instances, attracting attention from major private equity firms [1] - The electronics and computer industries each had two stocks in the top ten most researched, with Haiguang Information and Zhongke Shuguang both receiving 39 research instances, ranking second [1][2] Group 2 - The electronics industry was the most favored by private equity research, with 56 stocks receiving a total of 275 research instances [2][3] - The pharmaceutical and biological industry followed closely, with 41 stocks receiving a total of 266 research instances [3] - The mechanical equipment industry had 52 stocks that were researched a total of 234 times, while the computer industry had 36 stocks with 213 research instances [3] Group 3 - A total of 85 private equity institutions actively participated in A-share research, with Zhengyuan Investment being the most active, conducting 35 research instances [3] - Among the top ten private equity firms, two were billion-dollar firms, with Panjing Investment and Juming Investment conducting 19 and 13 research instances, respectively [3] - In June, 31 billion-dollar private equity firms participated in A-share research, totaling 176 research instances, with several firms conducting at least ten research instances [3]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - In June, private equity firms showed unprecedented activity in research, with 751 private securities managers participating in A-share listed company research, covering 387 stocks across 28 first-level industries, resulting in a total of 1,769 research instances [1] Group 2 - A total of 46 stocks received significant attention from private equity firms in June, with each stock having more than 10 research instances; 32 stocks received between 10 to 19 instances, while 14 stocks had over 20 instances [3] - Maiwei Biotech topped the list with 51 research instances, attracting interest from several major private equity firms [3] - Another notable stock in the pharmaceutical and biotechnology sector, Baili Tianheng, received 29 research instances, ranking among the top ten [3] Group 3 - Research activity was diverse across industries, with 21 first-level industries receiving at least 10 research instances from private equity firms; 11 industries had between 10 to 49 instances, 4 industries had between 50 to 99 instances, and 6 industries exceeded 100 instances [4] - The electronics industry was the most favored by private equity research, with 56 stocks collectively receiving 275 research instances [4] - The pharmaceutical and biotechnology sector followed closely, with 41 stocks receiving a total of 266 research instances [4] - The machinery equipment industry ranked third, with 52 stocks receiving a total of 234 research instances [4] - The computer industry had 36 stocks receiving 213 research instances, while both the automotive and basic chemical industries also surpassed 100 research instances, each with over 25 stocks [4]

Group 1 - The core viewpoint of the news is that Panjing Investment has conducted research on Maiwei Biotech, focusing on its collaboration with Calico to accelerate the clinical validation and commercialization of IL-11 monoclonal antibody (MW38) in anti-aging and fibrosis-related fields [1] - Maiwei Biotech's IL-11 monoclonal antibody has shown mechanisms of action in anti-aging and anti-fibrosis, with Calico interested in its potential for extending healthy lifespan [1] - MW38 has received clinical access approvals in China, the US, and Australia, with Phase I clinical trials completed in China and Australia, and preparations underway for the US clinical trials [1] Group 2 - Panjing Investment, established in 2016, is recognized as one of China's leading private equity fund managers, focusing on investment opportunities in Chinese listed companies and having a broad layout in overseas markets, especially in Chinese concept stocks [2] - The company emphasizes research-driven investment decisions, building a leading internal research team and maintaining strong relationships with top brokerage research institutes in China [2] - Panjing Investment aims to create long-term sustainable returns for clients by leveraging deep industry and individual stock research, along with solid value judgments to navigate different market cycles [2]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for future stock performance [1]. Core Insights - The company has entered a new phase of business development (BD) with two significant licensing agreements, which are expected to enhance cash flow and support future growth [2]. - The differentiated ADC (Antibody-Drug Conjugate) and TCE (T-cell Engager) platforms show promising potential, with several innovative products in the pipeline targeting various cancers [3]. - The company is strategically commercializing its products, with notable revenue growth in existing therapies and new product approvals anticipated [4]. Financial Projections - Total revenue is projected to grow significantly from 127.84 million in 2023 to 2,091.52 million by 2027, reflecting a compound annual growth rate (CAGR) of approximately 69.11% [1]. - The net profit is expected to improve from a loss of 1,053.43 million in 2023 to a loss of 226.00 million by 2027, indicating a trend towards profitability [1]. - The earnings per share (EPS) is forecasted to improve from -2.64 in 2023 to -0.57 in 2027, suggesting a gradual recovery in financial performance [1]. Business Development Highlights - The company has secured exclusive licensing agreements with Calico Life Sciences and Qilu Pharmaceutical, which will provide substantial upfront payments and milestone payments, enhancing liquidity [2]. - The ADC platform is actively developing multiple candidates, including Nectin4 ADC and B7-H3 ADC, with ongoing clinical trials expected to yield significant data in the near future [3]. - The TCE platform is also being developed with innovative strategies to enhance tumor targeting and efficacy, with IND applications anticipated in early 2026 [3]. Commercialization Strategy - The company has achieved significant revenue growth in its existing products, such as the osteoporosis treatment with a revenue increase of 230% year-on-year [4]. - Collaborations with established pharmaceutical companies are expected to leverage their sales capabilities, facilitating rapid market penetration for new products [4]. - The company is exploring unique marketing strategies to address aging-related medication needs in specific regions, potentially expanding its market reach [4].

Core Viewpoint - Maiwei Biotech is focusing on its innovative drug business development (BD) in 2025, aiming for breakthroughs in key pipeline projects such as Nectin-4 ADC, while acknowledging uncertainties in the BD business [1][2]. Group 1: Business Development (BD) Focus - 2025 is a critical year for the company's innovative drug BD business, with a focus on achieving substantial project outcomes [2]. - The company plans to expand its BD pipeline in 2026 to include new generation TCE platform-based projects, which are expected to have global differentiation advantages [2]. - The Nectin-4 ADC is currently in clinical research for multiple indications, with over 800 patients enrolled, and is leading in development progress globally for several indications [1][2]. Group 2: Clinical Research Progress - Three key Phase III clinical trials are ongoing: UC monotherapy, UC combination therapy, and CC monotherapy, with plans for interim analysis in 2026 and 2027 [3]. - The TNBC ADC therapy is in Phase II, with plans to initiate a small sample clinical trial in the U.S. in 2025 [3][4]. - The company is also advancing clinical trials for UC perioperative combination therapy and CC combination therapy, both of which have received approval [3]. Group 3: Product Advantages and Market Potential - The MW282 (Nectin-4 ADC) utilizes a new conjugation technology and has shown significant safety and efficacy, with a large patient population in need of new therapies for TNBC [4][5]. - The MW19 (anti-ST2 monoclonal antibody) is the second globally in clinical development for its target and is expected to read out Phase II data in late 2025 [5]. - The 9MW3011 (for polycythemia vera) is the first targeted TMPRSS6 monoclonal antibody in China, with a clinical trial planned for 2025, and is expected to offer better safety and convenience compared to existing treatments [6]. Group 4: Stock Lock-up and Shareholder Commitments - The company will not have any lock-up stock releases in July 2025, as shareholders have committed to not reducing their holdings until the company achieves profitability [7][8].